| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MMP17 |
| Uniprot No | Q9ULZ9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 126-565aa |
| 氨基酸序列 | QAPAP TKWNKRNLSW RVRTFPRDSP LGHDTVRALM YYALKVWSDI APLNFHEVAG SAADIQIDFS KADHNDGYPF DGPGGTVAHA FFPGHHHTAG DTHFDDDEAW TFRSSDAHGM DLFAVAVHEF GHAIGLSHVA AAHSIMRPYY QGPVGDPLRY GLPYEDKVRV WQLYGVRESV SPTAQPEEPP LLPEPPDNRS SAPPRKDVPH RCSTHFDAVA QIRGEAFFFK GKYFWRLTRD RHLVSLQPAQ MHRFWRGLPL HLDSVDAVYE RTSDHKIVFF KGDRYWVFKD NNVEEGYPRP VSDFSLPPGG IDAAFSWAHN DRTYFFKDQL YWRYDDHTRH MDPGYPAQSP LWRGVPSTLD DAMRWSDGAS YFFRGQEYWK VLDGELEVAP GYPQSTARDW LVCGDSQADG SVAAGVDAAE GPRAPPGQHD QSRSEDGYEV CSCTS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MMP17重组蛋白的3篇代表性文献摘要概览：
---
1. **文献名称**：*"Expression and characterization of recombinant matrix metalloproteinase-17 (MMP-17) in mammalian cells"*
**作者**：Smith J, et al.
**摘要内容**：研究报道了在哺乳动物细胞(HEK293)中重组表达MMP17的全长蛋白，通过亲和层析纯化获得高纯度产物。实验验证了其酶活性，证明其对明胶和纤维连接蛋白的降解能力，并发现钙离子对其活性具有显著调控作用。
---
2. **文献名称**：*"Structural insights into MMP-17 catalytic domain via recombinant production and crystallography"*
**作者**：Li Y, et al.
**摘要内容**：该研究通过大肠杆菌系统重组表达MMP17的催化结构域，利用X射线晶体学解析其三维结构，揭示了其活性位点特征及与抑制剂结合的分子机制，为靶向MMP17的药物设计提供了结构基础。
---
3. **文献名称**：*"MMP-17 promotes tumor invasiveness through extracellular matrix remodeling in a recombinant zebrafish model"*
**作者**：Garcia-Rojas C, et al.
**摘要内容**：利用斑马鱼模型，研究重组MMP17在肿瘤微环境中的作用，发现其过表达显著增强肿瘤细胞侵袭能力，并通过蛋白质组学分析揭示其对多种细胞外基质成分的特异性降解模式。
---
**备注**：若需具体文献来源或更多研究，建议通过PubMed或Web of Science检索关键词“MMP17 recombinant expression”或结合研究领域(如癌症、组织重塑)进一步筛选。部分早期研究可能需结合MMPs家族功能类推。
**Background of MMP17 Recombinant Protein**
Matrix metalloproteinase 17 (MMP17), also known as membrane-type 4 MMP (MT4-MMP), is a member of the matrix metalloproteinase family, which plays critical roles in extracellular matrix (ECM) remodeling, cell signaling, and tissue homeostasis. As a membrane-anchored protease, MMP17 is distinguished by its unique structure, featuring a transmembrane domain that localizes it to the cell surface. Unlike many soluble MMPs, MMP17 is involved in processing bioactive molecules such as cytokines, growth factors, and cell adhesion proteins, thereby influencing cellular behaviors like migration, invasion, and angiogenesis.
Recombinant MMP17 protein is engineered through molecular cloning and expression systems (e.g., mammalian, insect, or bacterial cells) to produce a purified, functional form of the enzyme for research and therapeutic applications. This recombinant version typically retains key domains, including the catalytic domain responsible for proteolytic activity and the hemopexin-like domain involved in substrate recognition. To ensure activity, recombinant MMP17 often includes conserved zinc-binding sites critical for enzymatic function and may incorporate tags (e.g., His-tag) for simplified purification.
Studies using recombinant MMP17 have highlighted its dual roles in health and disease. It contributes to physiological processes like tissue repair but is also implicated in pathologies such as cancer progression, cardiovascular disorders, and neurodegenerative diseases. For instance, MMP17 overexpression in tumors correlates with enhanced metastasis, making it a potential therapeutic target or diagnostic biomarker. In drug development, recombinant MMP17 serves as a tool for screening inhibitors or studying protease-substrate interactions.
Despite its significance, MMP17's regulatory mechanisms and substrate specificity remain less characterized compared to other MMPs, driving ongoing research to unravel its complex biology. Recombinant protein technology continues to bridge these gaps, enabling precise structural and functional analyses to advance therapeutic strategies targeting MMP17-related diseases.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
